Home
Shop Now
About Puriti Labs
Qualitative Analysis by Lot #
FDA
Contact Us
Customer Information
More
Open label evaluation of cannabidiol in dystonic movement disorders.
Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
Prospects for cannabinoid therapies in basal ganglia disorders
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent
properties
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease
Cannabidiol for the treatment of psychosis in Parkinson’s disease
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease
Therapeutic potential of cannabinoids in CNS disease